Navigation Links
Inovio Biomedical's DNA Delivery Technology Significantly Enhances,Potency of HIV DNA Vaccine

SAN DIEGO--(BUSINESS WIRE)--Mar 26, 2007 - Inovio Biomedical Corp. (AMEX:INO), which is focused on the development of DNA vaccines and a novel solid tumor ablation therapy, announced today that the Journal of Virology has published a scientific paper prepared by Inovio's development partner, Wyeth, regarding results from a non-human primate study of an investigational DNA vaccine against HIV delivered using Inovio Biomedical's electroporation technology. The paper, titled "Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques," summarized results of a research project lead by Michael A. Egan, Ph.D., a principle research scientist at Wyeth Vaccine Research. The scientific paper concluded: "These results indicate that in vivo electroporation appears safe and can dramatically improve the delivery and immunogenicity of a multi-vector, multi-antigen pDNA vaccine in non-human primates. Collectively, these data have important implications for the design and development of an efficacious therapeutic vaccine for the treatment of HIV-1 infection."

Key observations of the study included:

-- Vaccination in combination with in vivo electroporation led to a more rapid onset and enhanced vaccine-specific immune responses.

-- This increase in CMI (cell-mediated immune) responses translates to an apparent 50-200-fold (8 weeks and 22 weeks, respectively) increase in pDNA (plasmid DNA) vaccine potency.

-- Importantly, in vivo electroporation enhanced the immune response against the less immunogenic antigens, resulting in a more balanced immune response.

-- In addition, in vivo electroporation resulted in an approximate 2.5 log10 increase in antibody responses.

"Wyeth's non-human primate data demonstrated a significant increase in both the breadth and magnitude of the cellular immune response to selected HIV antigens . This is the type of response that virologists have been seeking for many years," stated Avtar Dhillon, MD, president and CEO of Inovio. "While these data will need to be reproduced in human clinical trials, the significant enhancement in potency observed to date reaffirms our position that electroporation is a key enabling technology for DNA vaccines."

Inovio's collaboration and non-exclusive license agreement with Wyeth was announced in November 2006.

About Inovio's DNA Delivery Technology

DNA vaccines have the potential to by-pass scientific obstacles inherent in the development of conventional vaccines. For example, DNA vaccines may be better in stimulating cellular immunity necessary to fight chronic infection or diseases such as cancer. Despite this promise, vaccination using DNA plasmid alone without enhanced delivery has not been shown to reach the threshold for clinical benefit.

Intramuscular delivery of DNA vaccines using Inovio's proprietary electroporation technology has been shown in primate studies to boost the immune response by orders of magnitude over DNA plasmid alone. Plasmid-based vaccines induced higher levels of antibodies and T-cell responses when delivered via electroporation, suggesting the potential to provide better protection from infectious diseases such as HIV and hepatitis C.

About Inovio Biomedical Corporation

Inovio Biomedical Corporation is focused on commercializing its Selective Electrochemical Tumor Ablation (SECTA) therapy and development of multiple DNA vaccines using its delivery platform for gene-based treatments. SECTA is a local ablation therapy for solid tumors that is designed to selectively kill cancerous cells and minimize cosmetic or functional impacts to predominantly healthy tissue typically treated around the tumor. Inovio is moving its lead product, the MedPulser(R), through pre-marketing studies for head and neck cancer and skin cancers in Europe, where it has CE Mark acc reditation, a U.S. phase III pivotal study for head and neck cancer, and a phase I/II trial for breast cancer. Inovio's DNA delivery partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, and the U.S. Army, with four gene-based therapies and DNA vaccines in phase I clinical studies. Inovio is a leader in developing human therapeutic applications of electroporation, which uses brief, controlled electrical pulses to dramatically increase cellular uptake of a useful biopharmaceutical, with the industry's most extensive patent portfolio covering in vivo electroporation. More information is available at

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology and about the availability of supporting internet technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical results referenced in this release may not be indicative of results achievable from testing in humans); the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of Inovio's technology as a delivery mechanism; the availability or potential availability of alternative therapies or treatments for the conditions targeted by Inovio or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio and its collaborators hope to develop; evaluation of potential opportunities; issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies; whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand c laims of invalidity; whether Inovio can finance or devote other significant resources that may be necessary to prosecute, protect or defend its proprietary rights; the level of corporate expenditures; assessments of our technology by potential corporate or other partners or collaborators; capital market conditions; and other factors set forth in the our Annual Report on Form 10-K for the year ended December 31, 2006, and other regulatory filings. There can be no assurance that any product in our product pipeline will be successfully developed or manufactured, or that final results of clinical studies will be supportive of regulatory approvals required to market licensed products.


Inovio Biomedical Corporation
Bernie Hertel, 858-410-3101 (Investor Relations)
Jeff Richardson, 805-491-8313 (Media Relations)


Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
3. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
4. Inovio: DNA delivery technology shows positive human results
5. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
6. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
10. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
11. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
Post Your Comments:
(Date:11/24/2015)... November 24, 2015 Sectra (STO: ... has entered into a multi-year agreement to deploy ... investment will provide the Breast Center a future-proof platform ... (STO: SECT B) announces that Breast Center of ... deploy Breast Imaging PACS in its two freestanding imaging ...
(Date:11/24/2015)...   HeartWare International, Inc . (NASDAQ: HTWR ... technologies that are revolutionizing the treatment of advanced heart ... Doug Godshall is scheduled to present at ... on December 1, 2015 at 3:00 p.m. ET.  The ... New York . . ...
(Date:11/24/2015)... , November 24, 2015 ... of the University of Bern ... Nutrition of the Bern University Hospital "Inselspital" are proud ... develop a novel generation artificial pancreas. Combining a fully ... for diabetic patients with the unequalled accuracy of an ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... , ... Many people know of the common symptoms of low thyroid hormone ... But many people who find their cholesterol levels and weight are creeping up are ... if they don’t have any of the other symptoms. , Thyroid hormone plays a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Students and parents ... awarded to winners of the Create Real Impact awards. California Casualty is ... help stem the tide of distracted and reckless driving, the number one killer of ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. Seidel, DMD ... benefits of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology ... by a dentist in Gettysburg, PA . From routine visits to cosmetic ...
(Date:11/24/2015)... AZ (PRWEB) , ... November 24, 2015 , ... Young ... 2.0™ treatments from Dr. Angela Wolfman and Dr. Kedar S. Lele, who are ... for frenectomies, cavities and fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort and ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... and variables that determine which patients are or are not eligible for bariatric surgery. ... a BMI over 40, are more than 100 pounds overweight, or have a BMI ...
Breaking Medicine News(10 mins):